Amgen UK&I Update Regarding COVID-19
As the COVID-19 situation continues to evolve, we want to assure all our customers and patients that we remain, as ever, committed to supporting patients to access the medicines they need and partnering with the NHS and HSE to deliver the best care to those who need it. We have taken several measures to protect the health and wellbeing of our staff so that we can continue to deliver for our patients during these unprecedented times.
We recommend that all patients using Amgen medicines who have questions or concerns about their treatment plan seek advice from their doctor.
For general information specific to a product, please click here.
Supply of our Medicines
We will continue to do everything in our power to provide an uninterrupted supply of medicines for patients around the world. Based on inventory levels, we do not anticipate a shortage of our medicines due to COVID-19 in the UK and Ireland at this time. However, we recognise this is a highly dynamic situation and are working with our partners throughout the supply chain to anticipate and mitigate risk wherever possible.
Staff and Customer Engagement
On Monday March 16, 2020 – in line with government guidance in both the UK and Ireland – we advised all staff members who can work from home to do so. We also made the decision to suspend all face-to-face visits to our NHS partners and customers until further notice, and took the decision to suspend business travel and attendance at medical congresses, conferences and other large events.
Since then, and in line with national changes to lockdown measures and government guidance (mindful that some regional variation continues to persist) we have been consulting with staff on the necessary arrangements for a safe and effective voluntary return to the workplace. In doing so, we have conducted a risk assessment of our office-based and field-based environments which has shaped the implementation of safety measures and staff guidance on workplace return.
Effective August 5th, 2020, we gave office-based staff in the UK the flexibility to return to the office on a voluntary basis, with consideration of their personal circumstances. We have put in place, and trained staff on, several measures to ensure their safety in the office.
Additionally, effective July 29th, 2020, field-based staff in the UK and Ireland also have the flexibility to return to face-to-face engagements on a voluntary basis, with consideration of their personal circumstances and those of the health system within their local geographies.
Our field colleagues are empowered and encouraged to partner with their customers through a number of engagement channels (virtual, phone, email, etc.) to ensure we meet customers’ needs as well as honouring our duty of care to staff to allow them to remain virtual-only if their circumstances require it.
This initial return phase in both the field and office is being kept under regular review as the national COVID-19 situations in both UK and Ireland continue to evolve. We are regularly monitoring for changes to government guidance and will continue to engage with our staff working parties in both the office and the field to review and adapt our plans and risk mitigation measures as appropriate.